

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 30, 2020

MIMEDX GROUP, INC.

(Exact name of registrant as specified in charter)

Florida
(State or other jurisdiction
of incorporation)

001-35887
(Commission
File Number)

26-2792552
(IRS Employer
Identification No.)

1775 West Oak Commons Ct., NE, Marietta GA 30062
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (770) 651-9100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	n/a	n/a

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On October 30, 2020, MiMedx Group Inc., (the "Company") issued a press release announcing that The Nasdaq Stock Market LLC approved its application for listing the Company's common stock on the Nasdaq Stock Market. A copy of the press release is attached hereto as exhibit 99.1 and is incorporated herein by reference.

It is expected that the Company's common stock will begin trading on the Nasdaq Stock Market at the opening of trading on or before November 5, 2020 under the symbol "MDXG".

Also on October 30, 2020, Timothy R. Wright, Chief Executive Officer of the Company published a letter to shareholders which discusses the Company's relisting on Nasdaq, having distributed its 2 millionth allograft, and future Company objectives. A copy of the letter to shareholders is attached hereto as Exhibit 99.2 and is incorporated herein for reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description of Exhibit
99.1	Press Release dated October 30, 2020
99.2	Letter to Shareholders dated October 30, 2020
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MIMEDX GROUP, INC.

Date: October 30, 2020

By: /s/ Peter M. Carlson

Peter M. Carlson
Chief Financial Officer

MiMedx Announces Relisting on Nasdaq

MARIETTA, Ga., October 30, 2020 -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and a therapeutic biologics company, today announced that The Nasdaq Stock Market LLC has approved MiMedx's application for the relisting of the Company's common stock on The Nasdaq Stock Market. The Company's common stock is expected to commence trading on The Nasdaq Stock Market at the opening of trading on or before Thursday, November 5, 2020, under the ticker symbol "MDXG". MiMedx's common stock will continue to trade on the OTC Pink Sheets until market close on the date before listing on the Nasdaq Stock Market under the ticker symbol "MDXG".

"Our relisting on Nasdaq is a momentous occasion that represents a transformative milestone for MiMedx's employees and shareholders. I would like to congratulate the entire MiMedx organization for this significant achievement," said Timothy R. Wright, MiMedx Chief Executive Officer. "Our relisting offers a broader range of investors access to our shares, improves trading liquidity, and strengthens our ability to execute swiftly on our strategic objectives. These initiatives include revenue growth expansion in advanced wound care by leveraging our placental tissue platform and advancing our promising late-stage pipeline across multiple markets. We remain focused on driving long-term shareholder value and making a meaningful difference for patients and their families through evidence-based technologies that help restore their quality of life."

About MiMedx

MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 2 million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contact

Hilary Dixon
Investor Relations & Corporate Communications
770.651.9066
investorrelations@mimedx.com



October 30, 2020

Dear Shareholder,

I am pleased to share news of a pivotal milestone: today, the Nasdaq Stock Market approved the relisting of MiMedx shares. Trading of our common stock, under the same ticker – MDXG – is expected to begin on or before November 5th. You can read more about the relisting in our [press release](#) issued this afternoon.

Relisting on Nasdaq has been our long-held intention. We continue to move beyond past challenges, and achieving this goal reflects our progress toward the next phase of our Company. While the relisting process took longer than you or I expected, we are here today, and I believe we are better positioned to realize the Company's value and growth potential. Restored access to the capital markets accomplishes two key objectives: it enhances value for you, our shareholders, and enables an increased dialogue by us with the financial community.

With a strong financial footing, the MiMedx team is moving forward to operationalize our vision and accelerate into the future. We are investing across our Commercial, Research and Development, and Manufacturing areas to drive near and long-term value, and I believe the objectives we have outlined set us on the path to achieve profitable growth, expand our core market, and continue to innovate by leveraging our leadership in placental science. The Company has scheduled November 4th to announce our Third Quarter 2020 Financial Results; November 20th to hold our 2020 Annual Shareholder Meeting; and we have additional planned outreach opportunities throughout the coming months to increase our dialogue with the financial community. I look forward to updating you on our continued progress.

Addressing the needs of our customers and patients is our motivation. As a market leader in amniotic tissue-based products for advanced wound care, it is our responsibility to accelerate the science and improve the standards of care for these individuals, increase the evidence that supports our versatile product platform, maximize the potential of our product offerings in the underserved, growing market of advanced wound care, and dedicate our efforts toward growing a successful and meaningful healthcare company. To that end, I am also pleased to share the recent milestone of distributing our **two-millionth allograft**. Our leading product portfolio continues to make a difference for patients with urgent, unmet need, who are waiting right now for hope and healing. These people and their families are at the heart of what we do.

On behalf of the entire MiMedx team, I thank you for your continued support and commitment to our journey. As always, I welcome your questions and feedback and look forward to engaging more fully and frequently with each of you.

Sincerely,
/s/ Timothy R. Wright
Timothy R. Wright
Chief Executive Officer
timothy.wright@mimedx.com
678.695.5146

Innovations In Regenerative Biomaterials

MiMedx Group, Inc. | 1775 West Oak Commons Ct NE | Marietta, GA 30062 | 770.651.9100 | Fax 770.590.3550 | www.mimedx.com

Important Cautionary Statement

This letter contains forward-looking statements. All statements relating to events or results that may occur in the future are forward-looking statements, including, without limitation, statements regarding achieving profitable growth, expanding our core market, and continuing to innovate; accelerating the science and improving the standards of care, increasing the evidence that supports our products, and future success. Forward-looking statements generally can be identified by words such as “expect,” “will,” “intend,” “seek,” “target,” “future,” “plan,” “continue,” “potential,” “possible,” “could,” “would,” “may,” “anticipate,” “to be,” “believe” and similar expressions. These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other factors that could significantly affect the Company’s operations and may cause the Company’s actual actions, results, financial condition, performance or achievements to differ materially from any future actions, results, financial condition, performance or achievements expressed or implied by any such forward-looking statements. Factors that may cause such a difference include, without limitation, those discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the period ended June 30, 2020.

Unless required by law, the Company does not intend, and undertakes no obligation, to update or publicly release any revision to any forward-looking statements, whether as a result of the receipt of new information, the occurrence of subsequent events, a change in circumstances or otherwise. Each forward-looking statement contained in this letter is specifically qualified in its entirety by the aforementioned factors. Readers are advised to carefully read this letter in conjunction with the important disclaimers set forth above prior to reaching any conclusions or making any investment decisions and not to place undue reliance on forward-looking statements, which apply only as of the date of this letter.

Innovations In Regenerative Biomaterials

MiMedx Group, Inc. | 1775 West Oak Commons Ct NE | Marietta, GA 30062 | 770.651.9100 | Fax 770.590.3550 | www.mimedx.com